John Pinching
- Indexed articles, last 90 days
- 19
- Latest publication
- Sep 29, 2026
- Outlet visibility, for PharmaTimes
- Top 5M sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Investor horizons ahead of CPHI 2026 - PharmaTimes (opens the original)
Read excerpt
The core merits of outsourcing drug research, development, manufacturing and packaging have been long established over 20 years of PE investment – access to specialist technology and expertise, cost advantages and accelerated speed to market. It is a testament to investor success that over 100 exhibitors at CPHI 2026 have some form of PE ownership across the entire value chain of outsourced pharma services, from excipients and APIs to FDFs and packaging (Figure 1). Nevertheless, navigating today
Buried knowledge could cost pharma billions. Here’s how to fix it - PharmaTimes (opens the original)
Read excerpt
A global pharmaceutical company already has the competitive report it needs. The problem is that the report is buried somewhere within the organisation’s information stores, and the marketing specialist who needs it cannot find it. They spend the next two days recreating work that someone else completed months earlier. What began as a knowledge-access issue becomes a measurable productivity cost. I call this research archaeology: skilled people digging through disconnected systems for knowledge
Buried knowledge - PharmaTimes (opens the original)
Read excerpt
A global pharmaceutical company already has the competitive report it needs. The problem is that the report is buried somewhere within the organisation’s information stores, and the marketing specialist who needs it cannot find it. They spend the next two days recreating work that someone else completed months earlier. What began as a knowledge-access issue becomes a measurable productivity cost. I call this research archaeology: skilled people digging through disconnected systems for knowledge
Building the future of clinical research around the patients it serves - PharmaTimes (opens the original)
Read excerpt
Clinical research is entering a new era: advances in methodological approaches, the growing integration of real-world evidence, and strengthened patient engagement are reshaping the drug development landscape.1As the field continues to evolve, an important challenge has emerged: does the evidence we generate truly reflect the populations these medicines are intended to serve? Across industry, regulators and the wider research ecosystem, there is growing recognition that answering this question w
Evolution - PharmaTimes (opens the original)
Read excerpt
Healthcare is evolving faster than ever. NHS reforms continue to reshape commissioning, integrated care systems are maturing and expectations of industry are changing. Success is no longer measured solely by product expertise, promotional excellence or a compelling brand message. Increasingly, it depends on understanding the health system, engaging customers in the context of their priorities and building partnerships that create measurable value for patients, services and the NHS. For pharmaceu
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For PharmaTimes, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.